Currently, the choice of first‐line treatment for advanced non‐small cell lung cancer (NSCLC) depends on the presence of genetic aberrations, such as mutations of epidermal growth factor receptor (EGFR) and translocations of anaplastic lymphoma kinase (ALK). Here, EGFR is linked to lung cancer.